Category: 65896-14-2

On October 31, 2012, WOJTASIAK-WYPART, M.; Soma, L. R.; Rudy, J. A.; Uboh, C. E.; Boston, R. C.; Driessen, B. published an article.Safety of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride The title of the article was Pharmacokinetic profile and pharmacodynamic effects of romifidine hydrochloride in the horse. And the article contained the following:

Romifidine HCl (romifidine) is an α2-agonist commonly used in horses. This study was undertaken to investigate the pharmacokinetics (PK) of romifidine following i.v. (i.v.) administration and describe the relationship between PK parameters and simultaneously recorded pharmacodynamic (PD) parameters. Romifidine (80 μg/kg) was administered by i.v. infusion over 2 min to six adult Thoroughbred horses, and plasma samples were collected and analyzed using liquid chromatog.-mass spectrometry. Limit of quantification was <0.1 ng/mL. PD parameters and arterial blood gases were measured for 300 min following romifidine administration. Statistical PD data anal. included mixed-effect modeling. After i.v. administration of romifidine, the plasma concentration-vs.-time curve was best described by a two-compartmental model. Terminal elimination half-life (t1/2β) was 138.2 (104.6-171.0) min and volumes for central (Vc) and peripheral (V2) compartments were 1.89 (0.93-2.39) and 2.57 (1.71-4.19) L/kg, resp. Maximum plasma concentration (Cmax) was 51.9 ± 13.1 ng/mL measured at 4 min following commencement of drug administration. Systemic clearance (Cl) was 32.4 (25.5-38.4) mL·min/kg. Romifidine caused a significant reduction in heart rate and cardiac index and an increase in mean arterial pressure (P < 0.05). Sedation score and head height values were significantly different from the baseline values for 120 min (P < 0.05). The decline in cardiovascular and sedative effects correlated with the decline in plasma romifidine concentration (P < 0.05). In conclusion, a highly sensitive anal. technique for the detection of romifidine in equine plasma allowed detailed description of its PK profile. The drug produces long-lasting sedation in horses that corresponds with the long terminal elimination half-life of the drug. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Safety of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

The Article related to sedivet pharmacodynamics pharmacokinetics sedative equus heart rate blood pressure, Pharmacology: Drug Metabolism and other aspects.Safety of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On August 5, 2004, Food and Drug Administration published an article.HPLC of Formula: 65896-14-2 The title of the article was Implantation or injectable dosage form new animal drugs; romifidine. And the article contained the following:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) field by Boehringer Ingelheim Vetmedica, Inc. The NADA provides for the veterinary prescription use of romifidine hydrochloride injectable solution in horses as a sedative and analgesic, and as a preanesthetic agent. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).HPLC of Formula: 65896-14-2

The Article related to romifidine standard injection horse, Pharmaceuticals: Drug Standards and other aspects.HPLC of Formula: 65896-14-2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On June 17, 2021, Pade, Remi; Charpentier, Gael; Villard, Isabelle published a patent.Synthetic Route of 65896-14-2 The title of the patent was Mite infestation treatment. And the patent contained the following:

The invention relates to a compound of the invention, a salt thereof or a composition containing same as an acaricide, to a method for reducing or preventing an infestation of an animal by a mite, comprising exposing the mite to a compound of invention, to a composition comprising a compound of invention and a polymer, to a strap or a beehive comprising a compound such as detomidine. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Synthetic Route of 65896-14-2

The Article related to miticides beehives cat collars dog, Agrochemical Bioregulators: Invertebrate and other aspects.Synthetic Route of 65896-14-2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 30, 2011, Kruger, Karin; Stegmann, George F.; Becker, Piet J. published an article.Reference of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride The title of the article was Preliminary investigation of concurrent administration of phenylbutazone and romifidine in healthy horses. And the article contained the following:

To characterize the cardiorespiratory and electrocardiog. effects of the combined administration of phenylbutazone and romifidine. Prospective four-period, four-treatment, blinded, randomized, crossover trial. Five, healthy, mixed breed horses. Prior to treatment administration, a catheter was introduced into the intra-thoracic cranial vena cava via the jugular vein and a s.c. located carotid artery was catheterised. All treatments were administered i.v. and consisted of saline placebo (PLC), phenylbutazone (PBZ, 4.4 mg/kg-1) romifidine (ROM, 80 μg/kg-1) and a combination of phenylbutazone (4.4 mg/kg-1) and romifidine (80 μg/kg-1). There was at least a 1 wk washout period between treatments. Heart rate (HR), respiratory rate (fR), systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressures and central venous pressure (CVP) were recorded for baseline (prior to drug administration) and at 5 min intervals thereafter for 30 min. Electrocardiog. abnormalities were recorded. Data were analyzed by ANOVA. For the cardiovascular variables there were no statistically significant (p > 0.05) differences between horses treated with ROM and PBZ_ROM. Statistically significant (p < 0.05) differences only occurred between treatments with romifidine (ROM and PBZ_ROM) and without romifidine (PLC and PBZ). Within treatments, for ROM, changes over time were statistically significant (p < 0.05) for HR, SAP, DAP, MAP and CVP. For PBZ_ROM, changes over time were statistically significant (p < 0.05) for CVP. Sino-atrial and atrio-ventricular blocks occurred in horses treated with ROM and PBZ_ROM. The combined i.v. administration of phenylbutazone and romifidine had no statistically significant effect on cardiorespiratory variables. These limited data suggest no evidence why both agents should not be included in a preoperative medication protocol for healthy horses but do not exclude the possibility of interactions occurring in a larger population. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Reference of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

The Article related to phenylarthrite sedivet anesthetic combination therapy heart rate respiration horse, Pharmacology: Drug Interactions and General Pharmacology and other aspects.Reference of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 12, 1978, Staehle, Helmut; Koeppe, Herbert; Kummer, Werner; Hoefke, Wolfgang published a patent.Product Details of 65896-14-2 The title of the patent was 2-Bromo-6-fluoro-N-2-imidazolidinylideneaniline. And the patent contained the following:

The title compound (I) and its pharmaceutically acceptable salts were prepared by the cyclization of 2,6-FBrC6H3NHC(SR):NH.HX (II; R = alkyl, X = halogen) with H2NCH2CH2NH2. Thus, II (R = Me, X = iodo) was refluxed with H2NCH2CH2NH2 in BuOH and the mixture treated with HCl to give 56.3% I HCl, which has antihypertensive activity comparable to that of clonidine, with fewer side effects, e.g., inhibition of gastric juice secretion. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Product Details of 65896-14-2

The Article related to antihypertensive phenyliminoimidazolidine, phenyliminoimidazolidine, imidazolidine phenylimino, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Product Details of 65896-14-2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 30, 2009, Leece, Elizabeth A.; Girard, Nicolas M.; Maddern, Kieren published an article.Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride The title of the article was Alfaxalone in cyclodextrin for induction and maintenance of anesthesia in ponies undergoing field castration. And the article contained the following:

To evaluate the induction and maintenance of anesthesia using alfaxalone following pre-anesthetic medication with romifidine and butorphanol in ponies undergoing castration in the field. Prospective clin. study. Seventeen male ponies weighing 169 ± 29 kg. The ponies were sedated with romifidine and butorphanol i.v. Induction time was recorded following administration of alfaxalone 1 mg/kg-1 and diazepam 0.02 mg/kg-1 i.v. If movement during surgery occurred, alfaxalone 0.2 mg/kg-1 was administered i.v. The quality of anesthetic induction, and recovery were scored on a subjective scale of 1 (good) to 5 (poor). The number of attempts to attain sternal recumbency and standing, quality of recovery and times from induction to end of surgery, first head lift, sternal recumbency and standing were recorded. Induction quality was good [median score (range) 1 (1-3)] with a mean ±SD time of 29 ± 6 s taken to achieve lateral recumbency. Ten ponies required incremental doses of alfaxalone during surgery. Mean times to the end of surgery, first head lift, sternal recumbency and standing were 26 ± 9 min, 31 ± 9 min, 33 ± 9 min and 34 ± 9 min resp. The number of attempts to attain sternal recumbency was 1(1-1) and to attain standing was 1(1-2). Quality of recovery was good, with a recovery score of 1(1-2). Alfaxalone provided smooth induction and recovery characteristics and was considered suitable for maintenance of anesthesia for castration in ponies. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

The Article related to alfaxan cyclodextrin anesthesia horse anesthetic, Mammalian Hormones: Corticosteroid, Gonadal, and Placental Hormones and other aspects.Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On November 5, 2020, Rosen, Yael; Dangoor, David; Fisher, Richard published a patent.HPLC of Formula: 65896-14-2 The title of the patent was Methods of treating pruritus by topically administering an α-2 adrenoreceptor agonist. And the patent contained the following:

The present disclosure related to methods of treating pruritus in a subject by topically administering an α-2 adrenoreceptor agonist to a subject. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).HPLC of Formula: 65896-14-2

The Article related to pruritus treatment topical alpha2 adrenoreceptor agonist, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.HPLC of Formula: 65896-14-2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 31, 2007, Buhl, Rikke; Ersboell, Annette K.; Larsen, Nanna H.; Eriksen, Lis; Koch, Joergen published an article.Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride The title of the article was The effects of detomidine, romifidine or acepromazine on echocardiographic measurements and cardiac function in normal horses. And the article contained the following:

To evaluate by echo- and electrocardiog. the cardiac effects of sedation with detomidine hydrochloride, romifidine hydrochloride or acepromazine maleate in horses. An exptl. study using a crossover design without randomization. Animals Eight clin. normal Standardbred trotters. Echocardiog. examinations (two-dimensional, guided M-mode and color Doppler) were recorded on five different days. Heart rate (HR) and standard limb lead electrocardiograms were also obtained. Subsequently, horses were sedated with detomidine (0.01 mg kg-1), romifidine (0.04 mg kg-1) or acepromazine (0.1 mg kg-1) administered i.v. and all examinations repeated. Heart rate before treatment with the three drugs did not differ significantly (p = 0.98). Both detomidine and romifidine induced a significant decrease (p < 0.001) in HR during the first 25 min after sedation; while acepromazine had a varying effect on HR. For detomidine, there was a significant increase in LVIDd (left ventricular internal diameter in diastole; p = 0.034) and LVIDs (left ventricular internal diameter in systole; p < 0.001). In addition, a significant decrease was found in IVSs (the interventricular septum in systole; p < 0.001), LVFWs (the left ventricular free wall in systole; p = 0.002) and FS% (fractional shortening; p < 0.001). The frequency of pulmonary regurgitation was increased significantly (p < 0.001). Romifidine induced a significant increase in LVIDs (p < 0.001) and a significant decrease in IVSs (p < 0.001) and FS% (p = 0.002). Acepromazine had no significant effect upon any of the measured values. The results indicate that sedation of horses with detomidine and to a lesser extent romifidine at the doses given in this study has a significant effect on heart function, echocardiog. measurements of heart dimensions and the occurrence of valvular regurgitation. Although the clin. significance of these results may be minimal, the potential effects of sedative drugs should be taken into account when echocardiog. variables are interpreted in clin. cases. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

The Article related to horse heart rate electrocardiog echocardiog domosedan sedivet plegicil sedative, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On July 31, 2014, Stine, Jessica M.; Michau, Tammy M.; Williams, Megan K.; Kuebelbeck, Karen Leann; Stengard, Michele E. published an article.SDS of cas: 65896-14-2 The title of the article was The effects of intravenous romifidine on intraocular pressure in clinically normal horses and horses with incidental ophthalmic findings. And the article contained the following:

Design : Original study. Objective : To evaluate the effect of sedation with romifidine hydrochloride 1% (Sedivet: Boehringer-Ingelheim) on intraocular pressure (IOP) in the normal horse and horses with incidental ophthalmic findings as measured by applanation tonometry. Animals : Nineteen clin. normal horses (13 geldings, six mares) and eight horses (three geldings, five mares) with incidental ophthalmic findings were included in this study. Procedures : All horses underwent complete ophthalmic examination with pharmacol. mydriasis a min. of 2 wk prior to IOP evaluation. Baseline intraocular pressure values were obtained following auriculopalpebral nerve block and topical anesthetic. Immediately thereafter, romifidine was administered i.v. (75 μg/kg) and the IOP recorded at 5, 15, 30, 45 and 60 min postsedation in both eyes. Five successive readings were obtained at each time point, the low and high value discarded, and three remaining readings averaged for a mean. Results : The changes with time were consistent between eyes and OD and OS results were pooled. The mean IOP at baseline was 26.35 ± 5.57 mmHg. Mean IOP values were significantly lower than baseline at 5 (P < 0.0001), 15 (P < 0.0001), 30 (P = 0.0003), 45 (P < 0.0001) and 60 (P = 0.0005) minutes. The largest change from baseline (16.7%) was noted at t = 15 min. Conclusions and clin. relevance : Administration of romifidine significantly decreased the IOP from baseline at all time points measured. The greatest decline in IOP was noted at 15 min postsedation. Results are consistent with other studies noting a decline in IOP with administration of α-2 agonists. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).SDS of cas: 65896-14-2

The Article related to sedivet alpha2 agonist intravenous drug delivery intraocular pressure horse, alpha-2 agonist, equine, intraocular pressure, romifidine, sedation, tonometry, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.SDS of cas: 65896-14-2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On July 31, 2014, Marzok, Mohamed A.; El-khodery, Sabry A.; Oheida, Aiman H. published an article.Category: imidazoles-derivatives The title of the article was Effect of intravenous administration of romifidine on intraocular pressure in clinically normal horses. And the article contained the following:

Objective : To evaluate the effect of i.v. administration of romifidine on the intraocular pressure (IOP) in horses. Animals studied : Twenty-four horses with no ocular abnormalities. Procedure : Horses were randomly assigned into two equal groups (treatment and control). All horses in the treatment group received an i.v. (IV) injection of romifidine (40 μg/kg). The horses in the control group were administrated an i.v. injection of 0.9% saline (0.4 mL/100 kg). In both groups, the IOP values were measured immediately (T0) pre-administration and at 5 (T5), 15 (T15), 30 (T30), 45 (T45), 60 (T60), 90 (T90), and 120 (T120) min after drug administration. Results : The pre-treatment values (T0) of IOP for right and left eyes were 24.25 ± 3.5 and 25.16 ± 3.4 mmHg, resp. A significant decrease in IOP values was observed in both right and left eyes of the horses in treatment group at T5, T15, T30, T45, T60, and T90 in comparison with the baseline values (P < 0.05). The lowest level of IOP in romifidine-treated groups was recorded at T45 for the right and left eyes (10.25 ± 2.3 and 11.25 ± 3.5 mmHg, resp.). Conclusion : Romifidine significantly decreased IOP in clin. normal horses and may be used safely for surgery or diagnostic ocular procedures in horses when specific control of IOP is required. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Category: imidazoles-derivatives

The Article related to sedivet alpha2 adrenoceptor agonist intraocular pressure horse antiglaucoma, applanation tonometry, horse, intraocular pressure, romifidine, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem